NasdaqGS:IDXXMedical Equipment
Is IDEXX’s Innovation-Fueled 2025 Results And 2026 Outlook Altering The Investment Case For IDXX?
In early February 2026, IDEXX Laboratories reported past fourth-quarter and full-year 2025 results showing double-digit gains in revenue and earnings, alongside initial 2026 guidance calling for US$4.63–US$4.72 billion in sales and earnings per share of US$14.29–US$14.80.
Management highlighted that growth was powered by Companion Animal Group Diagnostics, including record placements of new inVue Dx instruments and expanding Cancer Dx offerings, underscoring the impact of recent veterinary...